Growth Hormone / legal status / Last reviewed 2026-06-02

Tesamorelin Legal Status: Approval, Research Use, and Regulatory Notes

FDA approved (Egrifta). Prescription required. Schedule: Not a controlled substance.

Read the full Tesamorelin guide Browse answer pages

Direct Answer

Tesamorelin is FDA-approved for HIV-related lipodystrophy and has the strongest human evidence of any GHRH analog in this library - multiple Phase 3 RCTs demonstrating significant visceral fat reduction. Outside its approved indication, human data is limited. For research into GHRH-pathway GH stimulation, tesamorelin provides the reference standard with actual regulatory approval behind it.

Evidence grade
Level A
Research status
FDA Approved
Category
Growth Hormone
Best for
HIV-associated lipodystrophy, visceral fat reduction, GHRH-mediated GH research

Legal and Regulatory Status

FDA approved (Egrifta). Prescription required. Schedule: Not a controlled substance.

Approval Stage

Tesamorelin is listed as FDA Approved. Approved uses, if any, are indication-specific and do not automatically apply to other claims.

Compliance Notes

Evidence Page

For the complete evidence review, see the main Tesamorelin guide linked below.

Evidence Snapshot

Evidence gradeLevel A
Research statusFDA Approved
Best supported outcomesVisceral Adipose Tissue Reduction (Level A), IGF-1 Increase (Level A), and Cognitive Function (Level B)
Primary citation count3
Last reviewed2026-06-02

Related Guides

How to Cite This Page

ExaminePeptides. "Tesamorelin Legal Status: Approval, Research Use, and Regulatory Notes." Last reviewed 2026-06-02. https://examinepeptides.com/answers/tesamorelin-legal-status/

This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.